Pre-made Tepoditamab benchmark antibody ( Bispecific mAb, anti-CLEC12A/CD371;CD3E therapeutic antibody, Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tepoditamab (formerly MCLA 117) a bispecific, human IgG antibody (with a silenced region), is being developed by Merus for the treatment of acute myeloid.
| Products Name (INN Index) | Pre-Made Tepoditamab biosimilar, Bispecific mAb, Anti-CLEC12A/CD371;CD3E Antibody: Anti-CLL-1/CLL1/DCAL-2/MICL;T3E/TCRE/IMD18 therapeutic antibody |
|---|---|
| INN Name | Tepoditamab |
| Target | CLEC12A,CD3E |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | Genmab,Janssen Research & Development |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Acute myeloid leukaemia,Myelodysplastic syndromes |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CLEC12A,CD3E |
| Package |
